Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Many budgets falter due to vague goals, rigidity, or inconsistent tracking. Here’s why Why Most Budgets Do Not Work and how to fix it.
27,770 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
When a stock is Integer Stock Down 38%, some investors panic. Others see a chance to buy quality at a discount. This ...
New financing dynamics push builder optimism into 2026 even as demand concerns persist. A key survey shows a structur...
When Berkshire Hathaway's Greg Abel takes the stage as Buffett’s successor, the market watches not for flashy moves b...
SDNY prosecutors seek a new trial for Tornado Cash co-founder Roman Storm in October 2026, even as U.S. agencies ackn...
The Dow rose above a key threshold—49,683.30—on Thursday, putting it on a path to officially exit correction territor...
A major hedge fund just placed a multi-million bet on a biotech company after FDA approval. This article breaks down ...
As market swings redefine retirement planning, Americans over 50 recount the financial decisions they regret. This re...
A JPMorgan-led projection suggests about $165 billion in stock sales could hit markets as major funds rebalance portf...
If you already own Tesla, you may wonder whether SpaceX deserves a place in your investment mix. This guide breaks do...
This weekend, dive into 10 investing reads that translate to real-world gains—from fee awareness to tax planning and ...
A $250,000 SPIA promises $1,600 a month for life, but it comes with lock-in, fees, and a trade-off between predictabl...